Business
Theralase Announces Appointment of New Chief Executive Officers
TORONTO, ON / ACCESSWIRE / February 25, 2019 / Theralase Technologies Inc. (" Theralase 
...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Announces Appointment of New Chief Executive OfficersTORONTO, ON / ACCESSWIRE / February 25, 2019 / Theralase Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDCs\") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to announce the appointment of Shawn Shirazi, Ph.D., to the role of CEO of Theralase's Drug Division (\"CEO-Drug\") and Kipton Lade, B.Sc., M.Sc., MBA., to the role of Chief Executive Officer (\"CEO\") of Theralase's Device Division (\"CEO-Device\").Shawn Shirazi, Ph.D. Pharmacology obtained his B.Sc. in Chemistry from York University (Toronto, Ontario, Canada) and a M.Sc. and Ph.D. in Pharmacology from the University of Ottawa (Ottawa, Ontario, Canada).Dr. Shirazi brings over 20 years of hands-on experience in: pharmaceutical drug formulation and development, clinical trial management, Good Manufacturing Practices (\"GMP\") international drug manufacture, international regulatory guidelines and quality assurance in GMP drug manufacture. He has held senior roles with both start-ups and large pharmaceutical organizations, including: Executive Director and Vice President of Research and Development for Torpharm Inc (Division of Apotex (Apotex worldwide revenue $CAN 1.19 B (2016)), Senior Director Global Research and Development of Perrigo Company (NYSE: PRGO, $US 6.7 B Market Cap) and Chief Operating Officer - North America for Daxinganling Lingonberry Boreal Biotech Co. Ltd. (Leading manufacturer of high quality plant extracts, based in China), During his career, Dr. Shirazi has led the generic drug development programs for numerous pharmaceutical organizations, resulting in multiple \"First To File\" (\"FTF\") drug applications, allowing product exclusivity, as well as global leadership of research and development and merger and acquisition portfolios.Dr. Shirazi, CEO - Drug, Theralase stated, \"I am delighted to join the Theralase family with a mandate of developing and commercializing a truly amazing life saving technology. My expertise has been in directing high performance teams in formulating complex medicinal products and drugs, design of bioavailability & bioequivalence stud...